"I'EMPUS TEST REQUISITION FORM - 2024.04.30 Associated Study Study ID Phone: 800.739.4137 | Fax: 800.893.0276 | support@tempus.com If information is incomplete or missing, testing may be delayed. **A.PATIENT INFORMATION** ast Name MI First Name DOB (MM/DD/YYYY) Medical Record # Biological Sex Email Phone F City Address (Street, Unit) State Postal Code Country **B.ORDERING PHYSICIAN INFORMATION** Ordering Physician (full legal name) NPI# Facilitu Name Tempus Account # Email (required for report deliveru) Fax Country Facility Address (Street, Unit) City State Postal Code Additional person to be copied Form completed by Name Email/Fax Name Email/Fax Facility Name Facility Name **C.TESTING OPTIONS** Test descriptions Optional add-on tests (select all that apply): Common test combinations Specimen required xT: 648-gene DNA sequencing test with normal match; xR: whole transcriptome RNA sequencing test. FFPE Tissue; Normal: Blood or Saliva xT Solid Tumor, xR LDT xT (DNA) & xR (RNA): xT Normal Solid Tumor/Normal **FFPE Tissue** Blood or Saliva Add xF liquid biopsy at time of order, based on the following: 1 believe it is medically necessary to order a liquid biopsy test concurrently with a solid tumor tissue test because of one or more of the following reasons: (a) guidelines support the use of testing in this disease state; (b) turnaround time for tissue result may delay a treatment decision for my patient; (c) the tissue is at risk to fail (e.g. small tissue, archived tissue) and I may not have a timely result to make a treatment decision for my patient; (d) genomic heterogeneity may cause the patient's available tissue to not be completely representative, and I want to make sure I have a complete mutation PD-L1 IHC: DPYD UGT1A1 22C3 DEFAULT 28-8 SP142 If I have not already ordered an xF test above, I opt to convert my xT solid tumor order to an xF liquid biopsy test if necessary:SP263 By converting immediately OR After an additional tissue request is attempted MMR IHC HER2 IHC + FISH1,2 xT: 648-gene DNA sequencing test; xR: whole transcriptome RNA sequencing test. FFPE Tissue, Blood (EDTA), or Bone Marrow Aspirate (EDTA) xT (DNA) & xR (RNA): Solid Tumor OR Heme FOLR1 IHC FDA1 HRD¹ Individual test options Tumor Origin (RNA) FFPE Tissue, Blood (EDTA), or Bone Marrow Aspirate (EDTA) xR (RNA Only): Solid Tumor OR Whole transcriptome RNA sequencing test. Heme PurIST™ (RNA, Panc) 1 Powered bu NeoGenomics 2 For more information about reflex to FISH, please see Tempus? Reference Lab Logistics Overview at Tempus.com 3 Normal sample is required for ovarian or breast cancers FFPE Tissue, Blood (EDTA), or Bone Marrow Aspirate (EDTA) xT (DNA Only): Solid Tumor OR 648-gene DNA sequencing test xF (Liquid Biopsy): OR xF+ (Liquid Biopsy): xF: 105-gene or xF+: 523-gene liquid biopsy test for solid tumors. Blood (Streck) xG (CancerNext®) (Hereditary): Blood (EDTA), Saliva, or Cultured Fibroblast (cultured fibroblast specimen requires the completion of the Test Requisition for Tissue Culturing form). xG: 36-gene or xG+: 77-gene hereditary cancer test, powered by Ambry Genetics xG+ (CancerNext-Expanded®) (Hereditary): ${\tt D.SPECIMEN\ RETRIEVAL} \quad \textit{See Tempus' specimen guidelines for collection instructions and further details}.$ FFPE Tissue Pathology Lab (Name, City) Option 1: Option 2: Option 3: Specific specimen requested Let the submitting pathologist choose specimen Case Number Block # Date of Collection Biopsy to be scheduled for: Blood Saliva **Bone Marrow Aspirate Cultured Fibroblast** Mobile phlebotomy Sample previously submitted Send saliva kit to patient Date of Collection: Date of Collection: Date of Collection: Date of Collection: **E.CURRENT DIAGNOSIS** Primary ICD-10 Codes (C & D codes only) **NSCLC** Stage Other: Breast Pancreatic Other: 1 Ш Colorectal Ovarian Prostate Ш IV

Primary Insurance Plan Name Policy # Group# Policy Holder Name Policy Holder DOB Patient Relationship to Policy Holder Bill Type: Patient Status (for Medicare patients) Insurance Hospital/Institution Self pay/International Hospital Inpatient Date of discharge: Self Child Other: **G.PHYSICIAN SIGNATURE AND CONSENT** My signature below certifies that (1) the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s); (2) the ordered test(s) are medically necessary because the patient has been diagnosed with a cancer that is either recurrent, relapsed, refractory, metastatic, or advanced stage, and the test results will inform the patient's treatment plan; and Ordering Physician Signature (3) the patient has provided informed consent that meets the requirements of applicable law for Tempus or its reference lab to:
(a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s);
(b) obtain, receive, and release health information (including test results) as necessary for reimbursement or the processing of Today's Date (MM/DD/YYYY) insurance claims; (c) retain and use samples and health information for an indefinite period of time in accordance with applicable Printed Name (full legal name) law; and (d) de-identify such samples and information and use and share the resulting de-identified samples and information accordance with applicable law.

No

Yes -Type

Has the patient had any type of transplant?

Recurrent

Other:

Disease Status (select all that apply):

F.BILLING INFORMATION

Metastatio

Refractoru

Copy of patient's progress notes and/or medical records.

Copy of recent pathology report.

Copy of insurance card

The following fields are for xG (CancerNext®) or xG+ (CancerNext-Expanded®) orders ONLY. Disregard if not testing for hereditary cancers.

H.RELEVANT CLINICAL HISTORY (Previous cancer diagnosis, Gl polyps, etc.)

I.FAMILY HISTORY						
None/No known family history	Unknown	Adopted				
Relationship to patient	Ma	aternal Paternal	Age at diagnosis	Details of relevant historu		

J.ANCESTRY			K.BONE MARROW TRANSPLANT		
White/Caucasian	Native American	Middle Eastern	Personal history of allogenic bone marrow or peripheral stem cell transplant: Yes	No	
Hispanic	East Asian	Ashkenazi Jewish	Note: Using a blood or saliva sample is not appropriate for patients who have undergone an allogenic bone	allogenic bone	
Black/African American	South Asian	Other:	marrow or peripheral stem cell transplant.	_	

L.PRIOR PERSONAL OR FA	AMILY HISTORY OF GENETIC TESTING			
No personal or family history of molecular and/or genetic testing.		Relationship to patient: Self Family member:		
Germline testing Test performed: Results:		Microsatellite instability analysis: Stable (MSS) Unstable/High (MSI-High) Unstable/Low (MSI-Low)		
Somatic/tumor testing Test performed:	Results:	Immunohistochemical staining Proteins present: Proteins absent:		